OBEJECTIVETo compare the effectiveness of endometrial receptivity and pregnancy outcomes of four common immunomodulatory therapies for patients with thin endometrium.METHODThis systematic review and network meta-analysis using a literature search up to January 2024, to identify relevant trials comparing endometrial receptivity and pregnancy outcomes of human chorionic gonadotropin (hCG), platelet-rich plasma (PRP), infusion of granulocyte colony-stimulating factor (IG-CSF), and peripheral blood mononuclear cell (PBMC) for patients with thin endometrium. We used surface under the cumulative ranking (SUCRA) to ranked four common immunomodulatory therapies on endometrium thickness, implantation rate (IR), clinical pregnancy rate (CPR), and live birth rate (LBR). RoB2 and ROBINS-I were used to assess the certainty of evidence.RESULTSThe pooled results of 22 studies showed that hCG (mean difference [MD]: 3.05, 95% confidence interval [CI]: 1.46-4.64) and PRP (MD: 0.98, 95% CI: 0.20-1.76) significantly increase endometrium thickness. The hCG was the best among the IG-CSF (MD = -2.56, 95% CI = -4.30 to -0.82), PBMC (MD = -2.75, 95% CI = -5.49 to -0.01), and PRP (MD = -2.07, 95% CI = -3.84 to -0.30) in increasing endometrium thickness. However, IG-CSF and PRP significantly improved IR (IG-CSF: risk ratio (RR; IG-CSF: RR = 1.33, 95% CI = 1.06-1.67; PRP: RR = 1.63, 95% CI = 1.19-2.23), and LBR (IG-CSF: RR = 1.53, 95% CI = 1.16-2.02; PRP: RR = 1.59, 95% CI = 1.08-2.36).CONCLUSIONSAvailable evidence reveals that hCG and subcutaneous or intrauterine CSF (SG-CSF) may be the best treatment options for current thin endometrium patients. However, future high-quality and large-scale studies are necessary to validate our findings.

01 Dec 2024·Reproductive Biology

HLA-DQB1 as a potential prognostic biomarker of hormonal therapy in patients with non-obstructive azoospermia

Article

Author: Rozwadowska, Natalia ; Kamieniczna, Marzena ; Berger, Anna ; Stokowy, Tomasz ; Malcher, Agnieszka ; Kurpisz, Maciej ; Wolski, Jan Karol ; Jedrzejczak, Piotr

The gonadotropin treatment of infertile men may improve spermatogenesis and lead to sperm cell production, however, only a small fraction of treated patients positively responds to such therapy. To identify individual treatment prognostic biomarkers associated with responsiveness to gonadotropins, we compared the gene expression profiles of testicular oligobiopsies from 3 patients with non-obstructive azoospermia (NOA) who positively responded to therapy with a combination of human chorionic gonadotropin and recombinant follicle-stimulating hormone (hCG/rFSH) to those of 3 non-responders. We used Affymetrix Human Gene 1.0 ST microarrays. The results of the microarray evaluation were validated by the qPCR technique while gene variants of the HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) were subsequently sequenced. In our microarrays, we have identified most significantly 5 transcripts with different expression levels in responders versus non-responders groups. Our interest has been primarily focused on the transcript associated with the HLA-DQB1 gene. Because the expression of this gene was up-regulated in the non-responding patients and only patients with heterozygotic alleles of HLA-DQB1 turned out to be positive to gonadotropin therapy, we suggest that this gene may be a biomarker of potential significance for the gonadotropin treatment of male infertility. We also compared the testicular gene expression profile in one individual before and after gonadotropin treatment. In the re-biopsied sample, we have identified over 600 genes that showed differences in testicular expression; some of these genes are critical for spermiogenesis. Thus, we documented that the applied gonadotropins successfully stimulated the spermatogenetic wave in patients with NOA.

01 Nov 2024·Animal Reproduction Science

Relationship between the effect of human chorionic gonadotropin treatment on the fifth day after artificial insemination and ovarian ultrasonographic findings and blood nutritional metabolic factors in dairy cows

Article

Author: Endo, Natsumi ; Tanaka, Tomomi ; Kawahara, Naoya

The objective of the present study was to determine the ovarian ultrasonographic findings and metabolic factors that influence the effect of human chorionic gonadotropin (hCG) treatment on the fifth day after artificial insemination (AI) in dairy cows. Thirty-seven lactating Holstein cows were assigned to two groups: the hCG group (n = 25), which received 3000 IU of hCG intramuscularly on Day 5 after AI (day of AI = Day 0), and the control group (n = 12), which received no treatment. Ovarian ultrasonography measured luteal tissue area (LTA), luteal blood flow area (LBF), relative LBF (= LBF/LTA), and dominant follicle area on Day 5. Blood tests measured plasma insulin-like growth factor-I, insulin, and metabolite concentrations on Day 5 and plasma progesterone concentrations on Days 5 and 7. LBF was greater in pregnant cows than in non-pregnant cows, and plasma Glu concentration was lesser in pregnant cows than in non-pregnant cows, but in both cases there was no interaction between group and pregnancy outcome. For plasma insulin concentration, there was an interaction between group and pregnancy outcome, with pregnant cows in the hCG group having lesser concentrations than the other groups. Logistic regression analysis showed that group and the interaction between group and plasma insulin concentration were associated with pregnancy outcome. These results suggest that the effect of hCG treatment on Day 5 after AI is related to plasma insulin concentration and is more effective in cows with lesser plasma insulin concentrations.

News (Medical) associated with ACP-HIP(Quest PharmaTech)

09 Nov 2022

·www.prnewswire.com

Human Chorionic Gonadotropin (hCG) Market to grow by USD 303.49 Mn; Driven by an increase in the prevalence of infertility - Technavio

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- The " Human Chorionic Gonadotropin (HCG) Market by Technology and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The report expects the market size to grow by USD 303.49 million, accelerating at a CAGR of 6.7% during the forecast period. The report provides a detailed analysis of the factors influencing growth, vendor landscape, the latest trends, major revenue-generating segments, and regional growth opportunities. Understand the scope of the full report by Downloading Free PDF Sample Report. Market Dynamics: Continue Reading Technavio has announced its latest market research report titled Global Human Chorionic Gonadotropin (hCG) Market 2022-2026 The increasing infertility rate is one of the major reasons that drive the hCG market growth. According to a recent study, about 7% of married women aged 15-44 years in the US cannot get pregnant after a year of trying to conceive. Also, about 12% of women aged 15-44 years in the US have difficulty carrying a pregnancy to term, which is termed impaired fecundity. Most couples struggle with infertility and seek medical help for conception or pregnancy problems. In women, hCG improves ovulatory and final follicle maturation and offers luteal phase assistance during infertility treatment. This is expected to increase the demand for infertility treatment, which in turn, will drive the market growth during the forecast period. Get highlights into the impact of drivers, trends, and challenges on the growth of the global roti maker market. Download Free Sample Report Segmentation Analysis: Human Chorionic Gonadotropin (hCG) Market Technology Outlook (Revenue, USD Million, 2021-2026) Natural source extraction - size and forecast 2021-2026 Recombinant technology - size and forecast 2021-2026 The market growth will be significant in the natural source extraction segment over the forecast period. The rising prevalence of hypogonadism-related illnesses in men, particularly in older adults, is a primary growth factor in the segment. The segment will also be driven by the increased accessibility of infertility treatment and services, along with increasing infertility issues. Human Chorionic Gonadotropin (hCG) Market Geography Outlook (Revenue, USD Million, 2021-2026) North America - size and forecast 2021-2026 Europe - size and forecast 2021-2026 Asia - size and forecast 2021-2026 Rest of World (ROW) - size and forecast 2021-2026 North America will account for 37% of the global market share over the forecast period. The increase in the incidences of infertility and the growing awareness of infertility treatments are likely to fuel the growth of the market in North America. Also, changes in reimbursement policies on infertility treatments, medical tourism, and the rising number of vendors in the region will contribute to the growth of the regional market. Identify potential segments to invest in over the forecast period. Buy Report Now! Start for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Major Vendors in Human Chorionic Gonadotropin (hCG) Market: Biocare Medical LLC Cigna Corp. Cipla Ltd. Ferring B.V. Fresenius Kabi AG Intas Pharmaceuticals Ltd. Kamia Biomedical Company Lee BioSolutions Inc Lupin Ltd. Merck and Co. Inc. MyBioSource Inc. Prospec Tany Technogene Ltd. Sanzyme P Ltd. Scripps Laboratories Inc. Sun Pharmaceutical Industries Ltd. Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Related Reports: The peptide therapeutics market share is expected to increase to USD 23.36 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.52%. The increasing prevalence of infectious diseases is notably driving the peptide therapeutics market growth, although factors such as complexities in manufacturing, storage conditions, distribution policies, and high cost may impede market growth. The multiple myeloma drugs market size is expected to increase by USD 6419.94 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%. The growing incidence of multiple myeloma is notably driving the multiple myeloma drugs market growth, although factors such as the growing popularity of complementary and alternative medicine may impede the market growth. Table of contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Technology Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Technology 5.1 Market segments Exhibit 24: Chart on Technology - Market share 2021-2026 (%) Exhibit 25: Data Table on Technology - Market share 2021-2026 (%) 5.2 Comparison by Technology Exhibit 26: Chart on Comparison by Technology Exhibit 27: Data Table on Comparison by Technology 5.3 Natural source extraction - Market size and forecast 2021-2026 Exhibit 28: Chart on Natural source extraction - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Natural source extraction - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Natural source extraction - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Natural source extraction - Year-over-year growth 2021-2026 (%) 5.4 Recombinant technology - Market size and forecast 2021-2026 Exhibit 32: Chart on Recombinant technology - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Recombinant technology - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Recombinant technology - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Recombinant technology - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Technology Exhibit 36: Market opportunity by Technology ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 China - Market size and forecast 2021-2026 Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 Canada - Market size and forecast 2021-2026 Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 Cigna Corp. Exhibit 85: Cigna Corp. - Overview Exhibit 86: Cigna Corp. - Product / Service Exhibit 87: Cigna Corp. - Key offerings 10.4 Ferring B.V. Exhibit 88: Ferring B.V. - Overview Exhibit 89: Ferring B.V. - Product / Service Exhibit 90: Ferring B.V. - Key offerings 10.5 Fresenius Kabi AG Exhibit 91: Fresenius Kabi AG - Overview Exhibit 92: Fresenius Kabi AG - Business segments Exhibit 93: Fresenius Kabi AG - Key news Exhibit 94: Fresenius Kabi AG - Key offerings Exhibit 95: Fresenius Kabi AG - Segment focus 10.6 Intas Pharmaceuticals Ltd. Exhibit 96: Intas Pharmaceuticals Ltd. - Overview Exhibit 97: Intas Pharmaceuticals Ltd. - Product / Service Exhibit 98: Intas Pharmaceuticals Ltd. - Key offerings 10.7 Lee BioSolutions Inc Exhibit 99: Lee BioSolutions Inc - Overview Exhibit 100: Lee BioSolutions Inc - Product / Service Exhibit 101: Lee BioSolutions Inc - Key offerings 10.8 Lupin Ltd. Exhibit 102: Lupin Ltd. - Overview Exhibit 103: Lupin Ltd. - Product / Service Exhibit 104: Lupin Ltd. - Key news Exhibit 105: Lupin Ltd. - Key offerings 10.9 Merck and Co. Inc. Exhibit 106: Merck and Co. Inc. - Overview Exhibit 107: Merck and Co. Inc. - Business segments Exhibit 108: Merck and Co. Inc. - Key news Exhibit 109: Merck and Co. Inc. - Key offerings Exhibit 110: Merck and Co. Inc. - Segment focus 10.10 Sanzyme P Ltd. Exhibit 111: Sanzyme P Ltd. - Overview Exhibit 112: Sanzyme P Ltd. - Product / Service Exhibit 113: Sanzyme P Ltd. - Key offerings 10.11 Scripps Laboratories Inc. Exhibit 114: Scripps Laboratories Inc. - Overview Exhibit 115: Scripps Laboratories Inc. - Product / Service Exhibit 116: Scripps Laboratories Inc. - Key offerings 10.12 Sun Pharmaceutical Industries Ltd. Exhibit 117: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 118: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibit 119: Sun Pharmaceutical Industries Ltd. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 120: Inclusions checklist Exhibit 121: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 122: Currency conversion rates for US$ 11.4 Research methodology Exhibit 123: Research methodology Exhibit 124: Validation techniques employed for market sizing Exhibit 125: Information sources 11.5 List of abbreviations Exhibit 126: List of abbreviations About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

01 Dec 2021

·www.biospace.com

Assisted Reproductive Technology Drugs Treatment Market: The GnRH agonints segment is projected to account for a significant share of the market

Assisted reproductive technology (ART) comprises various medical procedures used to help in conception. Drugs play a major role in these procedures. The use of different classes of drugs in assisted reproduction has gained traction in recent years, due to a rise in prevalence of infertility. These drugs help at various phases of treatment in order to help with hormone regulation, triggered timed ovulation, and the prevention of ovarian hyperstimulation syndrome. Read Report Overview - A decline in fertility rates is anticipated to drive the global assisted reproductive technology drugs treatment market. According to a report published by the United Nations (UN), the total fertility rate was 2.5 children per woman globally in 2015. However, high procedural cost of assisted reproductive techniques and non-supportive government regulations for certain infertility treatment options are anticipated to hamper the market during the forecast period. Request Brochure of Report - Based on drug, the global assisted reproductive technology drugs treatment market can be classified into GnRH agonists, GnRH antagonists, gonadotropins, human chorionic gonadotropins, and others. The GnRH agonints segment is projected to account for a significant share of the market in the near future, as these drugs effectively work on endometriosis and help control the menstrual cycle. In terms of distribution channel, the global assisted reproductive technology drugs treatment market can be categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is expected to constitute a considerable share of the market during the forecast period, because the various processes of assisted reproduction are usually carried out in hospitals as patients need constant monitoring and checkups. Therefore, patients prefer to visit hospitals and buy drugs from hospital pharmacies for their convenience. Request for Custom Research - In terms of region, the global assisted reproductive technology drugs treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. The region is projected to account for a significant share of the global assisted reproductive technology drugs treatment market during the forecast period due to an increase in the number of infertility cases. According to the Centers for Disease Control and Prevention, in 2015, approximately 15% of couples in the U.S. were involuntarily infertile and depended on ART treatment to have their own child. Additionally, according to a report released by the Centers for Disease Control and Prevention, in 2016, the fertility rate in U.S. dropped to the lowest level ever recorded. This means that fewer babies are being born to women of childbearing age. Europe dominates the global assisted reproductive technology drugs treatment market due to factors such as issues of involuntary childlessness, favorable reimbursement policies, and regulation od ART treatment. Rise in tourism for surrogacy and low cost of the ART procedure in Asia Pacific compared to that in developed countries are driving the assisted reproductive technology drugs treatment market in Asia Pacific. A decline in fertility rates, rise in demand for fertility treatment, and investment by key players in the expansion of fertility clinics are some factors that are likely to propel the assisted reproductive technology drugs treatment market in Middle East & Africa during the forecast period. Pre Book Assisted Reproductive Technology Drugs Treatment Market Report - Major players operating in the global assisted reproductive technology drugs treatment market include AbbVie Inc., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Sun Pharma, and Abbott. More Trending Reports by Transparency Market Research: Surgical Kits Market The global society witnessing an unprecedented period of the coronavirus pandemic. The practice of surgery across the globe is witnessing a slowdown in activities. This is predicted to affect growth of the surgical kits market. As such, stakeholders in the value chain are increasing awareness about the new protocols and practices to combat the transmission of COVID-19 during critical surgeries. Acne Scar Treatment Market Unprecedented events caused by the COVID-19 pandemic have led to stressful environments, resulting in acne for both women and men. Stress related to coronavirus has worsen breakouts in individuals. Companies in the acne scar treatment market are capitalizing on this situation to increase the availability of topical treatments and in-office procedures. Intravascular Ultrasound [IVUS] Devices Market Ultrasound is among the imaging techniques that involves great interaction between patient and healthcare professional. Unless these techniques are carried out safely, it could increase risk of COVID-19 infection among physicians and patients. Such developments are predicted to affect growth in the intravascular ultrasound (IVUS) devices market. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

100 Deals associated with ACP-HIP(Quest PharmaTech)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB09126

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kaposi Sarcoma	Phase 1	-	University of Montréal	-
Kaposi Sarcoma	Phase 1	-	Quest PharmaTech, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis